je.st
news
Tag: treatment
FSP Finnish Steel Painting-Offshore Surface Treatment, Fireproofing and Engineering Services
2014-11-21 12:11:00| Offshore Technology
FSP Finnish Steel Painting (FSP) is one of the largest industrial surface treatment companies in Europe. It provides industrial surface treatments, fireproofing, floor coating, scaffolding, access te...
Tags: services
treatment
surface
engineering
Explore One of the Largest UV Water Treatment Plants in North America
2014-11-18 18:00:00| Electrical Construction & Maintenance
Project team completes water treatment plant in only 27 months thanks to aggressive, fast-track schedule read more
Tags: north
water
america
treatment
MANTECH Introduces 15-Minute COD Analysis For Municipal Wastewater Treatment Facilities
2014-11-17 04:13:40| pollutiononline Home Page
MANTECH INC., today announced the launch of PeCOD®, a patented nanotechnology based approach for Chemical Oxygen Demand (COD) analysis that overcomes the limitations of current COD analysis methods for municipal wastewater applications
Tags: analysis
treatment
facilities
municipal
ConocoPhillips Contracts CH2M HILL To Conduct Water Treatment Study
2014-11-17 02:10:21| oilandgasonline Home Page
ConocoPhillips (COP), in collaboration with industry Partners under the Petroleum Environment Research Forum (PERF), formulated a study out of its Water Centre in Doha, to identify and explore the application of new and more sustainable, cost-efficient water treatment technologies used in the production of oil and gas.
Tags: study
water
treatment
hill
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
Sites : [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] next »